ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Melanoma
Neoplasm Metastasis

Non-Small-Cell Lung Cancer trials near Atlanta, GA, USA:

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCL...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Atlanta, Georgia, United States and 36 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Dunwoody, Georgia, United States and 123 other locations

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (LIBRA)

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or m...

Enrolling
Non-Small Cell Lung Cancer
Drug: Ramucirumab
Drug: Rilvegostomig

Phase 2

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 56 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Atlanta, Georgia, United States and 256 other locations

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Enrolling
Non-Small Cell Lung Cancer
Drug: Telisotuzumab Vedotin

Phase 2

AbbVie
AbbVie

Marietta, Georgia, United States and 58 other locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the-...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 297 other locations

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non...

Active, not recruiting
Non Small Cell Lung Cancer (Stage III)
Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 117 other locations

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

resectable, early-stage non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Rilvegostomig

Phase 2

AstraZeneca
AstraZeneca

Gainesville, Georgia, United States and 97 other locations

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Austell, Georgia, United States and 347 other locations

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non...

Begins enrollment in 2 months
Non-Small Cell Lung Cancer (NSCLC)
Drug: Pumitamig
Drug: Pembrolizumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Douglasville, Georgia, United States and 249 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems